All Updates

All Updates

icon
Filter
Funding
Exsilio Therapeutics emerges from stealth with USD 82 million Series A funding
Cell & Gene Therapy
Jun 25, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Cell & Gene Therapy

Cell & Gene Therapy

Jun 25, 2024

Exsilio Therapeutics emerges from stealth with USD 82 million Series A funding

Funding

  • Exsilio Therapeutics, a biotechnology company developing genomic medicines, emerged from stealth raising USD 82 million in a Series A funding round co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, CRISPR Therapeutics, and others.

  • The funding will advance Exsilio's platform for developing genomic medicines based on naturally occurring genetic elements that can be delivered via mRNA and lipid nanoparticles to insert therapeutic genes into the human genome. 

  • Exsilio is developing a new class of genomic medicines that leverages mRNA technology to deliver genes that can permanently integrate into cells, offering the possibility of curative effects. The company's platform combines predictive modeling and experimentation to engineer genetic elements for precise gene insertion into safe harbor sites in the genome. The approach aims to enable redosable and titratable genomic medicines for genetic diseases, cancer, and autoimmune conditions.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.